{"id":"W6908355009","doi":"10.26190/unsworks/27739","title":"Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial","year":2019,"lang":"en","type":"article","venue":"UNSWorks (University of New South Wales, Sydney, Australia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Akebia Therapeutics; HLS Therapeutics; Servier; Relypsa; Astellas Pharma; Novo Nordisk; NxStage; Innovent Biologics; Amarin Corporation; Alnylam Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Canagliflozin; Type 2 diabetes; Kidney disease; Credence; Diabetes mellitus; Baseline (sea); Type 2 Diabetes Mellitus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003238108,0.0002434897,0.0005830963,0.0001482428,0.00008608952,0.00001305534,0.0001946389,0.00009296408,0.00003766361],"category_scores_gemma":[0.00009330497,0.0001868428,0.00009878168,0.0003474448,0.0002110966,0.0001825349,0.0001622932,0.0001837819,0.000002549244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001194653,"about_ca_system_score_gemma":0.0002671368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002126845,"about_ca_topic_score_gemma":0.0005023869,"domain_scores_codex":[0.9983212,0.0001209145,0.0002235761,0.0005066316,0.000523009,0.0003046608],"domain_scores_gemma":[0.9986686,0.0001003905,0.000240172,0.0005338251,0.0001080484,0.0003490146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0467589,0.0004577557,0.9372706,0.0003918114,0.002902221,0.00006291502,0.004342324,0.0006549281,0.00007719565,0.00002938165,0.002726015,0.004325981],"study_design_scores_gemma":[0.109709,0.002393548,0.8739427,0.005186571,0.003446396,3.802745e-7,0.002464513,0.0003057193,0.0001127797,0.00003597647,0.001939085,0.0004633684],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973834,0.0005776245,0.00001557816,0.0004426131,0.0000851449,0.001227367,0.0001920747,0.00001674957,0.00005944637],"genre_scores_gemma":[0.997406,0.0001338684,0.000435792,0.0000315023,0.00006770129,0.000001040685,0.0003464909,0.00001760742,0.001559963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06332791,"threshold_uncertainty_score":0.7619228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02758369359214911,"score_gpt":0.2229293996957503,"score_spread":0.1953457061036012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}